Favorable Early Response of Secondary Chronic Myeloid Leukemia to Imatinib

Dalia Waldman*, Michael Weintraub, Arnold Freeman, Yoram Neumann, Gideon Rechavi, Amos Toren

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

11 Scopus citations

Fingerprint

Dive into the research topics of 'Favorable Early Response of Secondary Chronic Myeloid Leukemia to Imatinib'. Together they form a unique fingerprint.

Keyphrases

Pharmacology, Toxicology and Pharmaceutical Science

Medicine and Dentistry

Biochemistry, Genetics and Molecular Biology